根治性前列腺切除术后淋巴结阳性前列腺癌的风险模型。

IF 1.8 3区 医学 Q3 UROLOGY & NEPHROLOGY
Kojiro Tashiro, Keiichiro Mori, Masaki Shiota, Wataru Fukuokaya, Dai Takamatsu, Yoshiyuki Matsui, Masashi Kato, Ryoichi Saito, Akira Yokomizo, Masakazu Tsutsumi, Yoshiyuki Yamamoto, Kohei Edamura, Makito Miyake, Shuichi Morizane, Takayuki Yoshino, Ryuji Matsumoto, Shintaro Narita, Hiroshi Kitamura, Masatoshi Eto, Takahiro Kimura
{"title":"根治性前列腺切除术后淋巴结阳性前列腺癌的风险模型。","authors":"Kojiro Tashiro, Keiichiro Mori, Masaki Shiota, Wataru Fukuokaya, Dai Takamatsu, Yoshiyuki Matsui, Masashi Kato, Ryoichi Saito, Akira Yokomizo, Masakazu Tsutsumi, Yoshiyuki Yamamoto, Kohei Edamura, Makito Miyake, Shuichi Morizane, Takayuki Yoshino, Ryuji Matsumoto, Shintaro Narita, Hiroshi Kitamura, Masatoshi Eto, Takahiro Kimura","doi":"10.1111/iju.70149","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Post-radical prostatectomy (RP) lymph node positivity (pN1) is associated with disease progression. However, the optimal treatment strategy for pN1 patients has remained unclear. This study aimed to establish a risk model for predicting survival outcomes in these patients.</p><p><strong>Methods: </strong>We retrospectively studied 528 eligible patients with pN1 undergoing RP with pelvic lymph node dissection between 2006 and 2019 at 33 participant institutions in the Japanese Urologic Oncology Study Group. Metastasis-free survival (MFS) was used to evaluate for survival outcome. A least absolute shrinkage and selection operator (LASSO)-penalized, multivariate Cox regression model for MFS was used to evaluate patients for their risk factors and establish a risk model with an associated nomogram.</p><p><strong>Results: </strong>Grade group (GGs 4-5 vs. GGs 1-3: HR, 7.35; 95% confidence intervals (CI), 1.76-30.7; p = 0.006), pathological T-stage (pT3b or more vs. pT2 to pT3a: HR, 2.01; 95% CI, 0.93-4.34; p = 0.075), number of positive lymph nodes (HR, 2.03; 95% CI, 0.83-4.96; p = 0.044), and positive lymph node diameter (> 2 mm vs. ≤ 2 mm: HR, 2.03; 95% CI, 1.09-9.00; p = 0.034) were identified as independent prognostic factors for predicting 60-month MFS.</p><p><strong>Conclusions: </strong>This study explored prognostic factors for pN1 prostate cancer patients for predicting their MFS and identified a risk model involving a nomogram. Randomized controlled trials are necessary in patients with pN1 prostate cancer to elucidate optimal postoperative treatment indications and selection.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.\",\"authors\":\"Kojiro Tashiro, Keiichiro Mori, Masaki Shiota, Wataru Fukuokaya, Dai Takamatsu, Yoshiyuki Matsui, Masashi Kato, Ryoichi Saito, Akira Yokomizo, Masakazu Tsutsumi, Yoshiyuki Yamamoto, Kohei Edamura, Makito Miyake, Shuichi Morizane, Takayuki Yoshino, Ryuji Matsumoto, Shintaro Narita, Hiroshi Kitamura, Masatoshi Eto, Takahiro Kimura\",\"doi\":\"10.1111/iju.70149\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Post-radical prostatectomy (RP) lymph node positivity (pN1) is associated with disease progression. However, the optimal treatment strategy for pN1 patients has remained unclear. This study aimed to establish a risk model for predicting survival outcomes in these patients.</p><p><strong>Methods: </strong>We retrospectively studied 528 eligible patients with pN1 undergoing RP with pelvic lymph node dissection between 2006 and 2019 at 33 participant institutions in the Japanese Urologic Oncology Study Group. Metastasis-free survival (MFS) was used to evaluate for survival outcome. A least absolute shrinkage and selection operator (LASSO)-penalized, multivariate Cox regression model for MFS was used to evaluate patients for their risk factors and establish a risk model with an associated nomogram.</p><p><strong>Results: </strong>Grade group (GGs 4-5 vs. GGs 1-3: HR, 7.35; 95% confidence intervals (CI), 1.76-30.7; p = 0.006), pathological T-stage (pT3b or more vs. pT2 to pT3a: HR, 2.01; 95% CI, 0.93-4.34; p = 0.075), number of positive lymph nodes (HR, 2.03; 95% CI, 0.83-4.96; p = 0.044), and positive lymph node diameter (> 2 mm vs. ≤ 2 mm: HR, 2.03; 95% CI, 1.09-9.00; p = 0.034) were identified as independent prognostic factors for predicting 60-month MFS.</p><p><strong>Conclusions: </strong>This study explored prognostic factors for pN1 prostate cancer patients for predicting their MFS and identified a risk model involving a nomogram. Randomized controlled trials are necessary in patients with pN1 prostate cancer to elucidate optimal postoperative treatment indications and selection.</p>\",\"PeriodicalId\":14323,\"journal\":{\"name\":\"International Journal of Urology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/iju.70149\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/iju.70149","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:前列腺根治术(RP)后淋巴结阳性(pN1)与疾病进展相关。然而,pN1患者的最佳治疗策略仍不清楚。本研究旨在建立预测这些患者生存结局的风险模型。方法:我们回顾性研究了2006年至2019年在日本泌尿肿瘤研究组的33个参与机构中接受RP并盆腔淋巴结清扫的528例符合条件的pN1患者。无转移生存期(MFS)用于评估生存结果。采用最小绝对收缩和选择算子(LASSO)惩罚的多变量Cox回归模型对MFS患者的危险因素进行评估,并建立带有相关nomogram风险模型。结果:分级组(GGs 4-5 vs GGs 1-3: HR, 7.35;95%置信区间(CI), 1.76-30.7;p = 0.006),病理t分期(pT3b及以上vs. pT2至pT3a: HR为2.01;95% ci, 0.93-4.34;p = 0.075),阳性淋巴结数(HR, 2.03;95% ci, 0.83-4.96;p = 0.044),阳性淋巴结直径(≤2 mm vs.≤2 mm: HR, 2.03;95% ci, 1.09-9.00;p = 0.034)被认为是预测60个月MFS的独立预后因素。结论:本研究探讨了pN1前列腺癌患者预测其MFS的预后因素,并确定了涉及nomogram风险模型。pN1前列腺癌患者需要随机对照试验来阐明最佳的术后治疗指征和选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.

Background: Post-radical prostatectomy (RP) lymph node positivity (pN1) is associated with disease progression. However, the optimal treatment strategy for pN1 patients has remained unclear. This study aimed to establish a risk model for predicting survival outcomes in these patients.

Methods: We retrospectively studied 528 eligible patients with pN1 undergoing RP with pelvic lymph node dissection between 2006 and 2019 at 33 participant institutions in the Japanese Urologic Oncology Study Group. Metastasis-free survival (MFS) was used to evaluate for survival outcome. A least absolute shrinkage and selection operator (LASSO)-penalized, multivariate Cox regression model for MFS was used to evaluate patients for their risk factors and establish a risk model with an associated nomogram.

Results: Grade group (GGs 4-5 vs. GGs 1-3: HR, 7.35; 95% confidence intervals (CI), 1.76-30.7; p = 0.006), pathological T-stage (pT3b or more vs. pT2 to pT3a: HR, 2.01; 95% CI, 0.93-4.34; p = 0.075), number of positive lymph nodes (HR, 2.03; 95% CI, 0.83-4.96; p = 0.044), and positive lymph node diameter (> 2 mm vs. ≤ 2 mm: HR, 2.03; 95% CI, 1.09-9.00; p = 0.034) were identified as independent prognostic factors for predicting 60-month MFS.

Conclusions: This study explored prognostic factors for pN1 prostate cancer patients for predicting their MFS and identified a risk model involving a nomogram. Randomized controlled trials are necessary in patients with pN1 prostate cancer to elucidate optimal postoperative treatment indications and selection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Urology
International Journal of Urology 医学-泌尿学与肾脏学
CiteScore
4.70
自引率
11.50%
发文量
340
审稿时长
3 months
期刊介绍: International Journal of Urology is the official English language journal of the Japanese Urological Association, publishing articles of scientific excellence in urology. Submissions of papers from all countries are considered for publication. All manuscripts are subject to peer review and are judged on the basis of their contribution of original data and ideas or interpretation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信